Inhibition of HER2 tyrosine kinase disrupts androgen-receptor functioning

被引：0
|
作者：
机构：
来源：
Nature Clinical Practice Urology | 2005年 / 2卷 / 6期
关键词：
D O I：
10.1038/ncpuro0192
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：264 / 265
页数：1
相关论文
共 50 条
  • [31] MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression
    Khan, Sheema
    Ebeling, Mara C.
    Sikander, Mohammad
    Yallapu, Murali M.
    Ise, Tomoko
    Nagata, Satoshi
    Behrman, Stephen W.
    Zafar, Nadeem
    Wan, Jim Y.
    Ghimire, Hemendra M.
    Sahay, Peeyush
    Pradhan, Prabhakar
    Jaggi, Meena
    Chauhan, Subhash C.
    CANCER RESEARCH, 2016, 76
  • [32] MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression
    S Khan
    M Sikander
    M C Ebeling
    A Ganju
    S Kumari
    M M Yallapu
    B B Hafeez
    T Ise
    S Nagata
    N Zafar
    S W Behrman
    J Y Wan
    H M Ghimire
    P Sahay
    P Pradhan
    S C Chauhan
    M Jaggi
    Oncogene, 2017, 36 : 491 - 500
  • [33] BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor for cancer therapy.
    Solca, F
    Baum, A
    Guth, B
    Colbatzky, F
    Blech, S
    Amelsberg, A
    Himmelsbach, F
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9025S - 9025S
  • [34] Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers
    Casolino, Raffaella
    Amato, Francesco
    Rae, Colin
    Puttagunta, Srikanth
    Braconi, Chiara
    JOURNAL OF HEPATOLOGY, 2022, 76 (05) : 1227 - 1229
  • [35] MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression
    Khan, S.
    Sikander, M.
    Ebeling, M. C.
    Ganju, A.
    Kumari, S.
    Yallapu, M. M.
    Hafeez, B. B.
    Ise, T.
    Nagata, S.
    Zafar, N.
    Behrman, S. W.
    Wan, J. Y.
    Ghimire, H. M.
    Sahay, P.
    Pradhan, P.
    Chauhan, S. C.
    Jaggi, M.
    ONCOGENE, 2017, 36 (04) : 491 - 500
  • [36] MUC13 Interaction With Receptor Tyrosine Kinase HER2 Drives Pancreatic Ductal Adenocarcinoma Progression
    Khan, Sheema
    Behrman, Stephen W.
    Zafar, Nadeem
    Jaggi, Meena
    Chauhan, Subhash C.
    GASTROENTEROLOGY, 2016, 150 (04) : S1203 - S1203
  • [37] Inhibition of ezrin causes PKCα-mediated internalization of erbb2/HER2 tyrosine kinase in breast cancer cells
    Jeong, Jaekwang
    Choi, Jungmin
    Kim, Wonnam
    Dann, Pamela
    Takyar, Farzin
    Gefter, Julia V.
    Friedman, Peter A.
    Wysolmerski, John J.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (03) : 887 - 901
  • [38] Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer
    Dhiwar, Prasad Sanjay
    Matada, Gurubasavaraja Swamy Purwarga
    Raghavendra, Nulgumnalli Manjunathaiah
    Ghara, Abhishek
    Singh, Ekta
    Abbas, Nahid
    Andhale, Ganesh Sakaram
    Shenoy, Ganesh Prasad
    Sasmal, Pujan
    MEDICINAL CHEMISTRY RESEARCH, 2022, 31 (09) : 1401 - 1413
  • [39] Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer
    Prasad Sanjay Dhiwar
    Gurubasavaraja Swamy Purwarga Matada
    Nulgumnalli Manjunathaiah Raghavendra
    Abhishek Ghara
    Ekta Singh
    Nahid Abbas
    Ganesh Sakaram Andhale
    Ganesh Prasad Shenoy
    Pujan Sasmal
    Medicinal Chemistry Research, 2022, 31 : 1401 - 1413
  • [40] Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer
    Mishra, Anurag
    Hourigan, David
    Lindsay, Andrew J.
    CANCER LETTERS, 2022, 529 : 153 - 167
12345